These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8840363)

  • 1. Cyclosporine neurotoxicity.
    Hauben M
    Pharmacotherapy; 1996; 16(4):576-83. PubMed ID: 8840363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine-A induced neurotoxicity after renal transplantation.
    Derici U; Arinsoy T; Sindel S; Tali T; Leventoglu A; Sert S
    Acta Neurol Belg; 2001 Jun; 101(2):124-7. PubMed ID: 11486560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine-induced white and grey matter central nervous system lesions in a pediatric renal transplant patient.
    Jeruss J; Braun SV; Reese JC; Guillot A
    Pediatr Transplant; 1998 Feb; 2(1):45-50. PubMed ID: 10084760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring.
    Grill MF; Maganti R
    Ann Pharmacother; 2008 Dec; 42(12):1843-50. PubMed ID: 19033476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression.
    Wijdicks EF; Wiesner RH; Krom RA
    Neurology; 1995 Nov; 45(11):1962-4. PubMed ID: 7501141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use.
    Behnam SM; Behnam SE; Koo JY
    J Drugs Dermatol; 2005; 4(2):189-94. PubMed ID: 15776776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cortical blindness secondary to cyclosporine after orthotopic heart transplantation: a case report and review of the literature.
    Drachman BM; DeNofrio D; Acker MA; Galetta S; Loh E
    J Heart Lung Transplant; 1996 Nov; 15(11):1158-64. PubMed ID: 8956125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
    Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
    Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adverse effects of drug interactions of cyclosporin A and tacrolimus therapy].
    Nowak JL
    Pol Merkur Lekarski; 2000 Sep; 9(51):634. PubMed ID: 11126995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine for severe ulcerative colitis.
    Pham CQ; Efros CB; Berardi RR
    Ann Pharmacother; 2006 Jan; 40(1):96-101. PubMed ID: 16368919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatologic and nondermatologic uses of thalidomide.
    Nasca MR; Micali G; Cheigh NH; West LE; West DP
    Ann Pharmacother; 2003 Sep; 37(9):1307-20. PubMed ID: 12921515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    Hermosillo AJ; Spinler SA
    Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neurotoxicity of cyclosporine].
    Kozłowska I; Rózańiski J; Ciechanowski K
    Wiad Lek; 2006; 59(7-8):516-20. PubMed ID: 17209351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered?
    Roedler R; Neuhauser MM; Penzak SR
    Ann Pharmacother; 2007 Apr; 41(4):653-8. PubMed ID: 17374625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple organ failure in a kidney transplant patient receiving both colchicine and cyclosporine.
    Minetti EE; Minetti L
    J Nephrol; 2003; 16(3):421-5. PubMed ID: 12832745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lip hypertrophy secondary to cyclosporine treatment: a rare adverse effect and treatment considerations.
    Bhattacharyya I; Islam MN; Yoon TY; Green JG; Ohja J; Liu JJ; Cohen DM
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):469-74. PubMed ID: 16997113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk factors conditioning the incidence and severity of cyclosporine A-induced gingival overgrowth and methods of prevention].
    Bartoli F; Castronovo G; Stabile A
    Minerva Stomatol; 2004 Apr; 53(4):165-70. PubMed ID: 15107773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients.
    Launay-Vacher V; Izzedine H; Deray G
    Int J Cardiol; 2005 May; 101(1):9-17. PubMed ID: 15860377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.